LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of September 18, 2026, LXRX stock price climbed to $2.05 with 6,037,177 million shares trading.

LXRX has a beta of 0.51, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.01 to the broad based SPY ETF.

LXRX has a market cap of $912.16 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $692,000 in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.

LXRX has outperformed the market in the last year with a return of +68.0%, while the SPY ETF gained +16.8%. However, in the most recent history, LXRX shares have underperformed the stock market with its stock returning +2.0% in the last 3 month period and -8.5% for the last 2 week period, while SPY has returned +2.3% and -0.9%, respectively.

LXRX support price is $1.97 and resistance is $2.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.